Press Releases

 Filter by Provider

Fohome, a top toilet factory, boasts 4M annual output, tech innovation and flexible OEM/ODM services for global wholesale toilet clients.

MED-TAC International Corp. is capitalizing on strong holiday season momentum with the launch of their 2026 Preparedness Initiative, designed to help organizations and families establish comprehensive emergency response capabilities in the new year.

Omnichannel360 announces expanded content marketing solutions for orthodontists in the highly competitive London market. Its services introduce updated SEO and AI strategies to capture patients across fragmented research journeys.

ContrastConnect has announced its virtual contrast supervision platform, offering services designed to reduce patient wait times through remote radiologist oversight.

ContrastConnect has announced that it will be providing CMS-compliant virtual contrast supervision for medical facilities seeking staffing solutions to the ongoing radiologist shortage.

ContrastConnect is offering updated virtual contrast supervision services to help imaging centers struggling with coverage amid the nationwide radiologist shortage.

From Lily Allen creating the ultimate diss album, Lewis Capaldi beating Drake and Kendrick, to Katy Perry’s space adventure impacting her ticket sales - a new report unlocks fans favourite moments in live music for this year.

LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, provides an update to the admission of new ordinary shares as announced on 18 December 2025.

The Magnum Ice Cream Company N.V.

The International Lawyers Network was named a finalist for Network of the Year at The Lawyer European Awards 2025, continuing its long history of recognition for excellence among global legal networks.

December 22, 2025 -- UroLux Concierge, founded and led by Urologist Dr. Esther Han, announces its grand opening for telehealth services and pre-scheduling for in-person care starting January 5th, 2026. UroLux is a concierge-model urologic and hormone optimization center.

December 22, 2025 -- Celebrate Christmas 2025 with Punyam Academy. Enjoy a Flat 20% Off on all ISO Documentation and Training Resources from 22nd to 31st December 2025. Perfect time to upskill during the festive and year-end learning season.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT.

Jersey City, NJ, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Meximodo Tequila announced the launch of Meximodo Tequila Blanco, a premium organic tequila introduced by entrepreneur Mehak Abrol, Founder and Chief Executive Officer of Meximodo Tequila. The announcement marks the company’s inaugural product release and establishes Meximodo Tequila as a woman-led entrant into the premium spirits category.

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL).

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC).

ENHERTU® (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the U.S. for adult patients with HER2 positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment and high risk of disease recurrence.

The first patient has been dosed in the DESTINY-Endometrial02 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) with or without radiotherapy compared to standard of care chemotherapy with or without radiotherapy as an adjuvant treatment (after surgery) in patients with HER2 expressing (IHC 3+/2+) endometrial cancer.

Three new projects in India will bring the Company’s global renewable energy capacity to 3.3GW

LONDON, UK / ACCESS Newswire / December 22, 2025 / Pantheon Resources plc (AIM:PANR)(OTCQX:PTHRF) ("Pantheon" or the "Company"), the oil and gas company developing the Kodiak and Ahpun oil fields near pipeline and transportation infrastructure on Alaska's North Slope, today issued a letter to shareholders from Pantheon Chairman David Hobbs.

Highlights:

JAB Insurance today announced that it has entered into a definitive agreement to acquire from Utmost Group plc its Life and Pensions business (“ULP”), a UK life and pensions platform with more than £5 billion of assets under management and serving approximately 290,000 pensioners.

Regulatory News:

COPENHAGEN, Denmark, Dec. 22, 2025 (GLOBE NEWSWIRE) -- A.P. Moller Capital, an institutional fund manager investing globally in critical infrastructure, has announced an investment through the A.P. Moller Capital - Emerging Markets Infrastructure Fund II in an Indian renewables joint venture with Rays Power Infra Limited (“Rays Power Infra”), a leading solar engineering, procurement and construction provider. The partnership will develop large-scale renewable projects across India, with the initial projects currently under development expected to reach a combined capacity of around 900 MW.

REYKJAVIK, Iceland, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that launches are underway in Europe for Gobivaz® (golimumab), Alvotech’s biosimilar to Simponi® (golimumab), also known as AVT05 (prefilled syringe and autoinjector). Gobivaz is the first marketed biosimilar to Simponi worldwide. It is being commercialized exclusively in Europe by Alvotech’s partner, Advanz Pharma Holdco Limited (“Advanz Pharma”).

SAN FRANCISCO, CA / ACCESS Newswire / December 22, 2025 / Nail It San Francisco, the top-notch spot for nail care and growing strategically at the center of the city, is quite hopeful of its new professional nail-tech training program. Led by the founder and master nail technician Irina Evglevskaya, this new initiative wishes to raise the level of nail art in San Francisco by revealing the secrets of the Russian manicure techniques.

Fort Lauderdale, Florida--(Newsfile Corp. - December 22, 2025) - Flood Relief, a professional water damage restoration company, announces the continued...

Apeing Coin, HYPE, XRP, ADA, AVAX, SOL, LINK, TRX shine as Apeing surges as the best upcoming crypto for 2026 with Whitelist live

Explore Apeing Coin, DOGE, APRZ, PENGU, WIF & BONK. Learn why Apeing Coin Whitelist is live and how these meme coins are the best crypto to watch now

Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has invested in and signed a strategic alliance agreement with Tulip Interfaces, Inc., a Massachusetts, USA-based leader no-code platforms for system operations without programming to support manufacturing digitalization. Tulip Interfaces is also an expert in introducing manufacturing-targeted microservices, which divide large-scale systems into small, independent services to enable flexible development and operations. Through this partnership, Mitsubishi Electric aims to build a no-code system-development platform to strengthen its digital-transformation (DX) solutions for manufacturing and other sectors.

New York, USA — GeekStake today shared a seasonal platform update as year-end activity increases across global digital asset networks.

Redwood City, USA — As the holiday season approaches, digital-asset platforms are observing changes in user activity patterns, with many

Regulatory News:

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELO™ (mosunetuzumab-axgb), as a subcutaneous (SC) formulation, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy, based on results from the Phase I/II GO29781 study. Based on the study results, Lunsumio VELO is approved under accelerated approval. Full approval for this regimen may be contingent on verification and confirmation of benefit in a confirmatory trial.

Amsterdam, 22 December 2025 --- AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) subsidiary AMG Lithium GmbH (“AMG Lithium”) is in the qualification phase before full commercial production at its lithium hydroxide refinery in Bitterfeld, Germany. After having completed ongoing customer testing of factory samples, the site will be the first industrial-scale battery-grade lithium hydroxide production facility in Europe, and by mid-2026 will operate at design capacity.

PARIS, FRANCE; 22 DECEMBER 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today an exclusive licensing agreement for global rights outside of Greater China, for SIM0613, an antibody-drug conjugate (ADC) with best-in-class potential. Targeting the LRRC15 protein, SIM0613 is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.

Regulatory News:

Geneva, Switzerland, December 22, 2025 – WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, today issued a Letter to Shareholders by its Founder and CEO, Carlos Moreira.

LOS ANGELES, CA / ACCESS Newswire / December 22, 2025 / PlanChecker AI, a leading innovator in AI-driven construction and architectural compliance, officially announced today that its groundbreaking "Interactive Plan Chat" feature is now available for purchase and public use. For the first time, homeowners, architects, engineers, contractors, developers, and even first-time applicants can instantly upload building plans and receive real-time, conversational analysis powered by advanced GPT intelligence; no corporate account, pre-approval, or specialized training is required.

JesusArt.art has released a new wall art collection centered on the life and teachings of Jesus. The collection features carefully designed prints created to bring peace, meaning, and Christ-centered focus into everyday living spaces.

Innovation continues unabated amidst the Web3 development wave. On December 19th, the x402 Builders Meetup, an industry conference focusing on the x402 ecosystem, successfully concluded at the Frontier Tower. Hundreds of developers and builders from the AI and Crypto fields gathered to discuss the development of the x402 ecosystem. MiniDoge, a leading Web3 ecosystem project, was invited to attend and deliver a speech, detailing its strategic layout in “DeFi + DePIN + AI public chain,” analyzing the path to realizing Web3 value under the x402 protocol, and injecting momentum into ecosystem collaboration and innovation.

e.l.f. Cosmetics, a brand from e.l.f. Beauty (NYSE: ELF), the bold disruptor with a kind heart, today announced the extension of its partnership with The Wonder Women of Wrestling Foundation (WWOWF) for a second consecutive year. e.l.f. returns as the first-ever beauty sponsor of the WWOWF Varsity Girls Wrestling Tournament on December 29-30, 2025, in Columbia, Missouri.

Snowflakes dance gently on Christmas Eve, as the city is bathed in a warm glow. For many couples, this is the most enchanting date night of the year. Yet, deciding what to wear—something that echoes the festive spirit without compromising personal style—has become a "sweet dilemma" for countless people.